<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313950</url>
  </required_header>
  <id_info>
    <org_study_id>HAF65</org_study_id>
    <nct_id>NCT00313950</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months
      Turkish children and check if the administration of the MMR trivalent vaccine on the same day
      but at different site will interfere on immunogenicity for the four valences Hepatitis A,
      Measles, Mumps, and Rubella.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immunogenicity of Hepatitis A Vaccine in subjects receiving Pediatric vaccines.</measure>
    <time_frame>Day 7 - Day 196</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">470</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella</intervention_name>
    <description>0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>AVAXIM™</other_name>
    <other_name>TRIMOVAX™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine</intervention_name>
    <description>0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>TRIMOVAX™</other_name>
    <other_name>AVAXIM™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella</intervention_name>
    <description>0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>AVAXIM™</other_name>
    <other_name>TRIMOVAX™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 12-13 months on the day of inclusion

          -  Born at full term of pregnancy (&gt;37 weeks) with a birth weight ≥ 2.5 kg

          -  Informed consent form signed by the parent(s) or other legal representative

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  Subjects having received only one or no injection of vaccine against Measles

          -  Subjects anti-HAV seronegative according to the results obtained at the screening
             visit*

        Exclusion Criteria:

          -  Participation in another clinical trial in the 4 weeks preceding the (first) trial
             vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term
             systemic corticosteroids therapy

          -  Systemic hypersensitivity to any of the vaccines components or history of a
             life-threatening reaction to the trial vaccines or a vaccine containing the same
             substances

          -  Chronic illness at a stage that could interfere with trial conduct or completion

          -  Blood or blood-derived products received in the past 3 months

          -  Any vaccination in the 4 weeks preceding the first trial vaccination

          -  Vaccination planned in the 4 weeks following any trial vaccination

          -  History of hepatitis A, Mumps, Measles and/or Rubella infection (confirmed either
             clinically, serologically or microbiologically)

          -  Previous vaccination against hepatitis A with the trial vaccine or another vaccine

          -  Previous vaccination against Mumps, Measles and Rubella with a Mumps, Measles and
             Rubella trivalent combined vaccine

          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination

          -  History of seizures

          -  Febrile illness (axillary temperature ≥37.4°C]) on the day of inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>13 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2006</study_first_submitted>
  <study_first_submitted_qc>April 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <last_update_submitted>January 17, 2014</last_update_submitted>
  <last_update_submitted_qc>January 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>measles</keyword>
  <keyword>rubella</keyword>
  <keyword>mumps</keyword>
  <keyword>hepatitis A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Measles</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Mumps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

